Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of FOR46 Administered Every 21 Days in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT03575819 is registered in ClinicalTrials.gov with Fortis Therapeutics, Inc. as lead sponsor.

NCT NCT03575819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03575819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of FOR46 Administered Every 21 Days in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Lead sponsor
Fortis Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 4, 2019
Completion date
November 22, 2023
Enrollment
56 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer metastatic